What Labcorp's Quarter ended Sep 30, 2026 10-Q says: 2 signals
Labcorp filed its latest 10-Q with the SEC on Oct 30, 2026. It discusses restructuring charge and software implementation.
Public (LH)Medical and Diagnostic Laboratories10,000+ employeeslabcorp.comLinkedIn
Get Labcorp's live signals in Claude or ChatGPT, or by API
What changed at Labcorp this week? Use Autobound signals for labcorp.com.- Filed
- Oct 30, 2026
- Period
- Quarter ended Sep 30, 2026
- Filings
- 3
- Signals
- 6
Source: Autobound Signal API · 75 signals tracked for Labcorp · updated
10-Q · latest 6
What Labcorp's 10-Q filings say
- SEC EDGAR
10-Q · Quarter ended Sep 30, 2026
Filed · 2 signals
The company is implementing a new ERP system and extending its deployment across broader areas of Labcorp.
ERP systemERP
Labcorp records $15.9 million in net restructuring and other charges in Q3 2026
During the three months ended September 30, 2026, the company recorded net restructuring charges of $15.9 million, consisting of $12.3 million in severance and personnel costs, $2.5 million in long-lived asset impairment, and $2.3 million in facility costs.
$15.9M
net restructuring and other charges recorded in Q3 2026
- SEC EDGAR
10-Q · Quarter ended Jun 30, 2026
Filed · 2 signals
Labcorp records $5.1 million in net restructuring charges for Q2 2026
During the three months ended June 30, 2026, Labcorp recorded net restructuring charges of $5.1 million, including $5.2 million for severance and personnel costs and $1.7 million in facility costs.
$5.1M
net restructuring and other charges recorded during Q2 2026
On July 4, 2025, the U.S. government enacted the OBBBA addressing healthcare funding and regulations, with provisions becoming effective through 2028 that could affect Medicaid and ACA coverage.
- SEC EDGAR
10-Q · Quarter ended Mar 31, 2026
Filed · 2 signals
Labcorp Secures $750.0M Term Loan Maturing in March 2028
On March 20, 2026, Labcorp entered into a $750.0 million term loan maturing March 20, 2028, to repay maturing debt and fund corporate uses.
$750M
2026 Term Loan principal balance
Labcorp Records $6.4M Net Restructuring Charges in Q1 2026
Labcorp recorded net restructuring charges of $6.4 million in the three months ended March 31, 2026, including $14.6 million in severance and personnel costs and $1.6 million in facility-related costs.
$6.4M
net restructuring and other charges
Earnings calls
Labcorp earnings headlines
From earnings call transcripts (Signal API type earnings-transcripts).
| Call date | What the company said |
|---|---|
| Raised 2026 revenue guidance midpoint by $65M to 6.3%The company increased its full-year 2026 enterprise revenue growth guidance to 5.9%–6.7% (a 50 bps increase at the midpoint) and raised adjusted EPS guidance to $18.30–$18.70. This increase reflects stronger underlying organic performance in central lab and diagnostics businesses. | |
| Acquired MLM Medical Labs and signed 3 tuck-in dealsDuring Q3, $256 million was deployed on acquisitions, including closing MLM Medical Labs to expand central lab footprint across four continents. Subsequent agreements were signed to acquire select assets of BioReference ($260M expected first-year revenue), Myriad Genetics' prenatal business ($100M revenue), and Millennium Health. | |
| Q3 revenue grew 6.9% to $3.8B, AOI margin 15%Third quarter revenue reached $3.8 billion, representing 6.9% year-over-year reported growth (5.5% organic). Adjusted operating income margin expanded 60 basis points to 15.0%, and adjusted EPS grew 14.5% to $4.78, demonstrating operational leverage. | |
| Biopharma segment revenue up 8.5% with $8.9B backlogBiopharma Laboratory Services (BLS) revenue reached $867 million, up 8.5% YoY (9.6% organic constant currency), driven by Central Lab Services growth of 11.3%. BLS backlog closed at $8.9 billion, with approximately $2.8 billion expected to convert to revenue over the next 12 months. | |
| Launched FDA cleared pTau217 test for Alzheimer's diseaseThe company expanded its neurology specialty testing by launching an FDA-cleared pTau217 blood biomarker test for Alzheimer's disease in primary and specialty care settings. It also rolled out a Hepatitis D reflex test and received FDA approval for a companion diagnostic in advanced melanoma using the PGDX platform. | |
| Building state of the art lab in IndianapolisCapital expenditures are planned at nearly 4% of total revenue as the company constructs a state-of-the-art central laboratory facility in Indianapolis to support accelerating biopharma demand. The multi-year capital commitment is incorporated into ongoing annual capex budgets. |
Signal API · MCP
Track Labcorp with the Signal API
One POST /v1/companies/enrich call with labcorp.com returns Labcorp 10-Q signals (sec-10q), each with its source. Or ask Claude through MCP.
2 credits per signal returned; zero-result calls are free. Endpoint reference
curl -X POST https://signals.autobound.ai/v1/companies/enrich \
-H "X-API-KEY: $AUTOBOUND_API_KEY" \
-H "Content-Type: application/json" \
-d '{"domain":"labcorp.com","signal_types":["sec-10q"],"limit":20}'Bulk data
Need this signal for 10,000+ companies?
Get a free sample file or a bulk feed (API, GCS push, flat file). The sample is real 10-Q Filings records, as a CSV.
Same industry
Related companies
Questions about Labcorp 10-Q
When did Labcorp file its latest 10-Q?
What did Labcorp disclose in its latest 10-Q?
What did Labcorp say on its recent earnings calls?
Where can I read Labcorp's 10-Q filing?
Page updated , the date of the newest row on this page.
Source. Quarterly reports (Form 10-Q) filed with the SEC. Every card links to the filing on EDGAR.
Method. Insights are extracted from the filing text and grouped by category. Numbers are quoted from the filing.
Data as of .